For a patient with a suspected urinary tract infection, the standard of care is a familiar, frustrating gauntlet. It involves securing a same-day appointment with a primary care physician or urgent care clinic, paying a co-pay or visit fee that can exceed $100, and waiting for a prescription to be called in. Chicago-based Scripted is building a health tech platform that aims to compress that journey into a single, affordable stop at the neighborhood pharmacy [MATTER Chicago, pre-2026].
Founded by former pharmacist James Lott, the company provides a software layer that enables pharmacists to diagnose and prescribe for a defined set of common, non-urgent conditions, including UTIs, influenza, COVID-19, strep throat, and even chronic disease management like asthma and hormonal birth control [Scripted.co/services/covid-19, retrieved 2026] [Newswire, retrieved 2026]. Patients can walk in or schedule an appointment, pay a consultation fee starting at $19, and leave with a prescription filled on the spot. The bet is not on novel AI, but on a pragmatic reconfiguration of existing healthcare assets and a slow-moving but steady shift in state-level prescribing authority.
The regulatory wedge
Scripted's entire model hinges on a patchwork of state regulations that allow pharmacists to prescribe for certain conditions. States like California, Texas, and Washington have passed laws enabling this practice, often with specific protocols and formularies [Scripted.co/pharmacists/pharmacy-medical-billing/pharmacy-billing-guidelines/, retrieved 2026]. The company's software acts as the operational engine for these new rules. It provides clinical decision support to guide the pharmacist through the assessment, automates the faxing of visit notes to the patient's primary care physician for continuity, and handles the complex medical billing required to get the pharmacy visit reimbursed by health plans [Perplexity Sonar, retrieved 2026]. For Lott, who holds a PharmD and a Master of Public Policy, the mission is to empower his former colleagues.
The patient and pharmacy value proposition
The appeal is a straightforward trade: convenience and lower cost for the patient, a new revenue stream for the pharmacy. For someone who needs an antibiotic for a UTI or a refill of their birth control pill, a $19-$39 visit at a known location with no appointment needed is a compelling alternative to a more expensive and logistically difficult doctor's visit. For the pharmacy, especially independent operators, it represents a chance to move beyond dispensing into higher-value clinical services. Scripted's website lists a partner pharmacy in Fremont, California, as an early deployment site [Scripted.co/pharmacies/hallers-pharmacy-fremont-california, retrieved 2026].
The capital and traction question
Scripted's public footprint is light, which makes gauging its scale and momentum difficult. The company has raised an undisclosed amount of capital, with total funding reported at approximately $485,000 from a consortium of non-traditional venture backers including the UCSF Rosenman Institute, Village Capital, and Techstars [PitchBook, retrieved 2026]. It has participated in the MATTER Chicago incubator. There is no public disclosure of revenue, patient volume, or a broad roster of pharmacy partners.
- Regulatory friction. The business is entirely dependent on the continued expansion and stability of pharmacist prescribing laws.
- Pharmacy adoption. Convincing pharmacy chains to integrate new software and retrain staff is a heavy lift.
- Competitive landscape. Large retail pharmacy chains may develop similar capabilities in-house, and other telehealth platforms could seek to partner directly with pharmacists.
The company's early support from public health-focused institutions like the Rosenman Institute suggests its model is viewed as a legitimate access-to-care solution. The next twelve months will be critical for the company to move from a promising pilot with a single pharmacy in California to a demonstrable network, proving that its software can reliably unlock this new layer of care at scale.